• Presented at Rare Patient Advocacy Summit (2021)

  • Collaborator: Sanofi Genzyme

  • Authors: Patricia Ann McGee Watson, Florence Joly, Lisa Anne Schmitt, Emilie Pain, Damien Testa

Cold Agglutinin Disease (CAD) is a rare disease and type of autoimmune hemolytic anemia characterized by autoantibodies that bind to red blood cells at below core body temperature. In addition to cold-induced symptoms, the anemia and hemolysis observed in CAD causes numerous symptoms including fatigue, dizziness, shortness of breath, headaches; reported in very few publications. Disease severity may fluctuate. There is no approved drug for the treatment of CAD.

Objective: The present study aims to assess the impact of CAD and its related effects on patients’ daily life.